Technologies announced today that on April 10, NYSE American publicly announced and provided a notice to the company that NYSE ...

Palatin Technologies, Inc. (the "Company") (NYSE American:PTN), a biopharmaceutical company developing first-in-class ...

NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Palatin ...

CRANBURY, N.J. - Palatin Technologies (NYSE:PTN), Inc. (NYSE American: PTN), a biopharmaceutical firm with a market capitalization of $23.22 million, has announced a new funding round through a ...

36% had reduced urinary synaptopodin losses, indicating healthier kidney cells and structure. Palatin Technologies, Inc. "The positive results from our Phase 2b study evaluating a melanocortin ...

CRANBURY, N.J., April 10, 2025 /PRNewswire/ -- Palatin Technologies ... Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange (the "Panel").